

Publication of Kazuo Umezawa in 2012. Articles in Japanese are removed, so there are gaps in number.

340. E. Ota, M. Takeiri, M. Tachibana, Y. Ishikawa, K. Umezawa and S. Nishiyama: Synthesis and biological evaluation of molecular probes based on the 9-methylstreptimidone derivative DTCM-glutarimide. *Bioorganic & Medicinal Chemistry Letters* 22:164-167, 2012.

341. T. Fukushima, M. Kawaguchi, K. Yorita, H. Tanaka, K. Umezawa, H. Kataoka: Antitumor effect of dehydroxymethylepoxyquinomicin (DHMEQ), a small molecule inhibitor of nuclear factor- κ B, on glioblastoma. *Neuro-Oncology* 14: 19-28, 2012.

342. H. Hosoi, N. Kawai, H. Hagiwara, T. Suzuki, A. Nakazaki, K. Takao, K. Umezawa and S. Kobayashi: Determination of the absolute structure of (+)-akaterpin. *Chem. Pharm. Bull.* 60:137-143, 2012

343. T. Funakoshi, K. Yamashita, N. Ichikawa, M. Fukai, T. Suzuki, R. Goto, T. Oura, N. Kobayashi, T. Katsurada, S. Ichihara, M. Ozaki, K. Umezawa, and Satoru Todo: A novel NF- κ B inhibitor, dehydroxymethylepoxyquinomicin, ameliorates inflammatory colonic injury in mice. *Journal of Crohn's and Colitis*, in press.

344. C. Alberti, P. Pinciroli, B. Valeri, R. Ferri, A. Ditto, K. Umezawa, M. L. Sensi, S. Canevari, and A. Tomassetti: Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via NF κ B pathway on advanced-stage epithelial ovarian cancer. *Oncogene*, in press.

346. M. Kawata, D. Koinuma, T. Ogami, K. Umezawa, C. Iwata, T. Watabe and K. Miyazono: TGF- β -induced epithelial-mesenchymal transition of A549 lung adenocarcinoma cells is enhanced by proinflammatory cytokines derived from RAW 264.7 macrophage cells. *J. Biochem.*, in press.

347. R. Saito, S. Yamada, Y. Yamamoto, T. Kodera, A. Hara, Y. Tanaka, F. Kimura, I. Takei, K. Umezawa and I. Kojima: Conophylline suppresses pancreatic stellate cells and improves islet fibrosis in Goto-Kakizaki rats. *Endocrinology*, in press.

348. J. A. McCubrey, S. L. Abrams, K. Umezawa, L. Cocco, A. M. Martelli, R. A. Franklin, W. H. Chappell, L. S. Steelman: Novel approaches to target cancer initiating

cells—Eliminating the root of the cancer. *Advances in Enzyme Regulation*, in press.

349. R. Goto, K. Yamashita, T. Aoyagi, S. Ueki, M. Uno, T. Oura, N. Kobayashi, R. Igarashi, S. Shibasaki, K. Wakayama, G. Hirokata, T. Shibata, K. Umezawa, M. Ozaki, and S. Todo: The immunomodulatory effect of nuclear factor- κ B inhibition by dehydroxymethylepoxyquinomicin in combination with donor-specific blood transfusion. *Transplantation*, in press.

350. M. Takeiri, E. Ota, S. Nishiyama, H. Kiyota, S. Simizu and K. Umezawa: Structure-activity relationship of 9-methylstreptimidone that induces selective apoptosis in adult T-cell leukemia cells. *Oncology Res.*, in press.

351. M. Takeiri, K. Horie, D. Takahashi, M. Watanabe, R. Horie, S. Simizu and K. Umezawa: Involvement of DNA binding domain in the cellular stability and importin affinity of NF- κ B component RelB. *Org. Biomol. Chem.*, in press.

352. N. Lampiasi, A. Azzolina¹, K. Umezawa, G. Montalto, J. A. McCubrey and M. Cervello: The novel NF- κ B inhibitor DHMEQ synergizes with Celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. *Cancer Lett.*, in press.

353. A. M. Castro-Gamero, K. S. Borges, V. da Silva Silveira, R. C. P. Lira, R. de Paula G. Queiroz, F. C. P. Valera, C. A. Scrideli, K. Umezawa and L. G. Tone: Inhibition of nuclear factor- κ B by dehydroxymethylepoxyquinomicin induces schedule-dependent chemosensitivity to anticancer drugs and enhances chemoinduced apoptosis in osteosarcoma cells. *Anti-Cancer Drugs*, in press.

354. K. Hinohara, S. Kobayashi, S. Simizu, K. Tada, E. Tsuji, K. Nishioka, K. Umezawa, M. Mori, H. Kanauchi, T. Ogawa, J. Inoue, A. T and N. Gotoh: ErbB/NF κ B signaling controls self-renewal of breast cancer stem cells. *Proc. Natl. Acad. Sci. USA*, in press.